Dietary Supplement for Joint: the OLE Study

Overview

This clinical study evaluates if the oral administration of Bonolive can contribute to the improvement of functionnality in healthy elderly people with knee discomfort.

Full Title of Study: “Effect of Oleuropein-based Dietary Supplement (Bonolive™) Versus Placebo on Knee Joint Functionality and Cartilage Catabolism in Ageing Population”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Basic Science
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: April 30, 2018

Interventions

  • Dietary Supplement: Bonolive
    • 2 caps per day of Bonolive
  • Dietary Supplement: Placebo
    • 2 caps per day of Placebo

Arms, Groups and Cohorts

  • Experimental: Bonolive
  • Placebo Comparator: Placebo

Clinical Trial Outcome Measures

Primary Measures

  • Evaluation of the effect of investigational product after 6 months of supplementation
    • Time Frame: From Baseline to 6 months of product administration and compared to Placebo
    • KOOS (Knee injury and Osteoarthritis Outcome Score)
  • Evaluation of the effect of investigational product after 6 months of supplementation
    • Time Frame: From Baseline to 6 months of product administration and compared to Placebo
    • Biomarker of cartilage breakdown (Coll2.1-NO2)

Secondary Measures

  • Evaluation of the effect of investigational product
    • Time Frame: From Baseline to 6 months of product administration and compared to Placebo
    • Knee pain VAS score at rest and at walking
  • Evaluation of the effect of investigational product
    • Time Frame: From Baseline to 6 months of product administration and compared to Placebo
    • OARSI core set of performance-based tests

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female ≥ 55 years of age
  • BMI between 18.5 and 29.9 kg/m2 (normo and overweight)
  • Moderate knee pain (the most painful knee is considered)
  • Able to follow the instructions of the study
  • Able to perform physical tests
  • Having signed an informed consent

Exclusion Criteria

Related to knee

  • Recent trauma (< 1 month) of the knee responsible of the symptomatic knee
  • Subject with knee/joint surgery/replacement and ACL (Cross Ligament) injury in the target knee
  • Concurrent articular disease interfering with the evaluation of pain such as articular dysplasia, aseptic osteonecrosis, acromegaly, Paget's disease, hemophilia, hemochromatosis, chondromatosis, villonodular synovitis of the knee, seronegative spondyloarthropathy, rheumatoid arthritis, gouty arthritis , infectious arthritis, radiculalgia in the lower limbs, arteritis
  • Prosthesis in the target knee
  • Diagnosed arthrosis eligible to knee/joint surgery/replacement

Related to treatments

  • Analgesics to manage knee pain 24h before inclusion visit
  • Corticosteroids injection in the target knee in the month preceding inclusion
  • Hyaluronan injection in the target knee in the last 6 months
  • Oral corticotherapy ≥ 5mg/day in the last 3 months
  • Symptomatic slow-acting drugs (SYSADs) treatment (Chondroitin, diacerein, glucosamine, soy and avocado unsaponifiables) in the last 3 months
  • Other dietary supplements used for articular disorders in the last 3 months
  • An anticipated need for the duration of the trial of corticosteroids or hyaluronan injection, oral corticotherapy, arthroscopy, analgesics other than listed as rescue treatments, which are forbidden during the trial
  • Arthroscopy in the last 6 months
  • Allergy or contra-indication to Oleuropein, to maltodextrin or any ingredient present in the product, or intolerance to rescue treatment (Paracetamol and NSAIDs)
  • Treatments based on strontium ranelate, bisphosphonates, selective estrogen-receptor modulator (SERM) and parathormone (PTH) during the year before inclusion

Related to associated diseases

  • Severe and uncontrolled diseases (liver or renal failure, lung/heart severe disease, Parkinson, progressive malignant neoplasia or in remission for less than 5 years, HIV, etc.)
  • Lower or upper extremity surgery or fracture in the last 3 months
  • Anticipated need for any surgical or other invasive procedure during the trial including prosthesis in the target knee
  • Swallowing disorder

Related to patients

  • Close collaborators to the investigational team, the study coordinator (Artialis) or to the Sponsor (Nestlé)
  • Currently participating or having participated in another therapeutic clinical trial in the three previous months
  • Having made a blood donation in the past month
  • Under guardianship or judicial protection
  • Pregnancy, breastfeeding, planned conception
  • Premenopausal women or women without tubal ligation or contraception.

Gender Eligibility: All

Minimum Age: 55 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Nestlé
  • Collaborator
    • Artialis
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.